Development of pharmacophore model to identify potential DNA gyrase inhibitors

Abstract

There is great concern in the medical community due to rapid increase in antibiotic resistance, causing 700,000 deaths annually worldwide. Therefore, there is paramount need to develop novel and innovative antibacterial agents active against resistant bacterial strains. DNA gyrase is a crucial enzyme in bacterial replication that is absent in eukaryotes, making it effective curative target for antibacterials. To identify potential DNA gyrase inhibitors by virtual screening of NCI database using a 3-step approach. A total of 271 compounds with known IC50 values against Escherichia coli DNA GyrA were selected to develop a pharmacophore model for dual screening approach to identify new potential hits from the NCI database. In the second step, the NCI database was also screened using in-house built NN-QSAR model. Molecular docking of common 5298 compounds screened from both methods were performed against E. coli DNA GyrA (PDB id- 6RKU), and 3004 compounds are reported to exhibit lower binding energies than ciprofloxacin (−6.77 Kcal/mol). The top three compounds (NCI371878, NCI371876 and NCI142159) reported with binding energy of −13.5, −13.19 and −13.03 Kcal/mol were further subjected to MD simulation studies for 100 ns supporting the stability of the docked complexes.

Graphical Abstract

Communicated by Ramaswamy H. Sarma

Keywords:

• DNA GyrA
• pharmacophore model
• QSAR model
• molecular docking
• molecular dynamic simulations

Acknowledgments

The authors acknowledge “DBT Builder Maharshi Dayanand University Interdisciplinary Life Science Programme for Advance Research and Education” for providing the necessary support and facilities for the completion of this research work.

Disclosure statement

None declared.

Funding

The author(s) reported there is no funding associated with the work featured in this article.